证券之星消息，1月23日中药板块较上一交易日上涨0.28%，*ST长药领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收于14439.66，上涨0.79%。中药板块个股涨跌见下表： 从资金流向上来看，当日中药板块主力资金净流出5.1亿元，游资资金净流出5225.91万元，散户资金净流 入5.62亿元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000538 | 云南白药 | 2925.96万 | 3.91% | 124.39万 | 0.17% | -3050.36万 | -4.07% | | 002390 | 信邦制药 | 1707.83万 | 9.03% | -877.49万 | -4.64% | -830.34万 | -4.39% | | 600750 江中药业 | | 1112.58万 | 4.76% | 719.17万 | 3.08% | -- 1831. ...

Core Viewpoint - Yiling Pharmaceutical (002603.SZ) is expected to turn a profit in 2025, with net profit and net profit excluding non-recurring items projected to reach between 1.2 billion to 1.3 billion yuan, and basic earnings per share expected to rise to between 0.72 yuan and 0.78 yuan [1][2]. Financial Performance - The net profit attributable to shareholders is forecasted to be between 1.2 billion and 1.3 billion yuan, a significant recovery from a loss of approximately 724.5 million yuan in the same period last year [2]. - The net profit excluding non-recurring items is also expected to be between 1.2 billion and 1.3 billion yuan, compared to a loss of about 792.5 million yuan in the previous year [2]. - Basic earnings per share are projected to improve to between 0.72 yuan and 0.78 yuan, up from a loss of 0.43 yuan per share in the prior year [2]. Strategic Initiatives - 2025 is identified as a critical year for the company's "13th Five-Year Plan," focusing on long-term development amidst market complexities and competitive pressures [3]. - The company is enhancing budget management and establishing a comprehensive cost control system, leading to improved profit margins [3]. - Significant investment in R&D, with 544 million yuan allocated in the first three quarters of 2025, representing 9.27% of revenue, positions the company as a leader in the traditional Chinese medicine sector [3]. Product Development - Core products such as Qiliqiangxin Capsules and Tongxinluo Capsules have received validation from international medical journals, supporting their market promotion [3]. - The company is seeing notable sales growth in patented traditional Chinese medicine products, with Baizi Bujin Capsules becoming a major OTC product exceeding 100 million yuan in sales [3]. Expansion into Chemical Drugs - The company is actively expanding into the chemical drug sector, with several innovative drugs entering clinical trials [5]. - The approval of the chemical drug Anilofen Injection, the first patented chemical drug from its subsidiary Yiling Wanzhou, marks a significant milestone for the company [5]. - Anilofen Injection is positioned as a new treatment option for postoperative pain management, enhancing the company's product pipeline in the chemical drug market [5]. Industry Context - The continuous decline in traditional Chinese medicine material prices since mid-2024 has positively impacted the company's performance, alleviating cost pressures [6]. - The comprehensive price index for traditional Chinese medicine materials has decreased from nearly 3600 points in July 2024 to 2556 points by January 2026, returning to early 2021 levels [6]. - Analysts from various firms have recognized the company's strong R&D and sales capabilities, suggesting a valuation premium due to its strategic positioning in both traditional and chemical medicine sectors [6].

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [4][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, with a decline of 0.75% from January 9 to January 22, 2026, lagging behind the index by approximately 0.46 percentage points [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials leading the gains at 3.14% and 2.34%, respectively. In contrast, the pharmaceutical distribution and chemical preparation sectors experienced declines of 3.26% and 2.87% [12][13]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, showing a weekly increase of 60.88%. Conversely, Luyan Pharmaceutical had the largest decline at 39.07% [13][16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry index showed a decline of 0.75%, underperforming the Shanghai and Shenzhen 300 index by 0.46 percentage points [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, while pharmaceutical distribution and chemical preparations faced declines [12]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement and usage [24]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of its drug registration certificate for a new injection, which is expected to enhance its market position [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted as a key area for future growth. Specific companies to watch include Mindray Medical, Yuyuan Medical, and others across various segments [26][28].

● 本报记者 李梦扬 根据同花顺iFinD数据，截至1月22日记者发稿时，按照申万一级行业划分，已有逾50家生物医药企业披 露2025年业绩预告，27家预喜，预喜比例近五成。值得关注的是，多家CXO（医药外包服务，包括 CDMO和CRO）公司业绩表现亮眼。其中，CXO行业龙头药明康德预计2025年实现营业收入约454.56亿 元，同比增长约15.84%；实现归母净利润约191.51亿元，同比增长约102.65%。 业内人士表示，随着全球投融资逐步恢复、国内对创新药行业的持续支持以及新药研发逐步回暖， CXO产业趋势向好。2026年，随着行业结构性改革深化、政策与融资环境持续优化，中国医药产业提 质升级趋势明确，行业将迈向高质量发展新阶段。 27家生物医药公司业绩预喜 在已披露业绩预告的超50家生物医药公司中，27家预喜，其中，18家预增，5家略增，4家扭亏。从归母 净利润金额看，药明康德预计2025年实现归母净利润191.51亿元，位居第一；以岭药业、甘李药业、兴 齐眼药、华邦健康等公司居前，预计归母净利润下限均超5亿元。 剔除扭亏影响，从归母净利润同比变动下限看，上海谊众、康辰药业、特一药业、昭衍新药等多家 ...

Group 1 - Southbound funds reduced their holdings in China Traditional Chinese Medicine (00570.HK) by 994,000 shares on January 22 [1] - Over the past five trading days, southbound funds have reduced their holdings for four days, with a total net reduction of 4.59 million shares [1] - In the last 20 trading days, there were eight days of net increases in holdings by southbound funds, totaling 256,000 shares [1] Group 2 - China Traditional Chinese Medicine Holdings Limited primarily engages in the manufacturing and sales of traditional Chinese medicine [2] - The company operates through four divisions, focusing on the production and sales of traditional Chinese medicine formula granules, health products, and traditional Chinese medicine slices [2] - The Tianjiang division also provides healthcare solutions related to traditional Chinese medicine through offline medical institutions, including consultations and prescriptions [2]

Group 1 - The core point of the article is that Guilin Sanjin has reported a total of 18,963 shareholders as of January 20, 2026 [2]

Group 1 - The company, Guilin Sanjin (002275), responded to investor inquiries on January 22, indicating that the company secretary is primarily responsible for information disclosure, investor relations management, organizing board and shareholder meetings, and compliance governance [1] - For specific details, the company advised to refer to the "Board Secretary Work System" document, which will be disclosed in December 2025 [1]

证券日报网讯 1月22日，特一药业发布2025年度业绩预告称，公司预计2025年度归属于上市公司股东的 净利润为7000万元—9000万元，比上年同期增长241.55%—339.13%。 （文章来源：证券日报） ...

Core Viewpoint - The company, Chongqing Taiji Industry (Group) Co., Ltd., announced a capital increase of 46.7 million yuan for its wholly-owned subsidiary, Yuncheng Taiji Smart Traditional Chinese Medicine Co., Ltd., to enhance its financial stability and market competitiveness [1] Group 1: Capital Increase Details - The registered capital of Yuncheng Smart Traditional Chinese Medicine will increase from 300,000 yuan to 47 million yuan following the capital injection [1] - The capital increase aims to supplement the subsidiary's working capital, optimize its asset-liability structure, and enhance its capital strength and risk resistance [1] Group 2: Strategic Importance - The traditional Chinese medicine resource sector is a key component of the company's strategic planning [1] - The investment is intended to ensure stable supply of traditional Chinese medicine materials, strengthen market expansion, and cultivate core product brands [1] Group 3: Risk Management and Financial Impact - The company emphasized that the capital increase aligns with its strategic layout and long-term interests, with overall risks being controllable [1] - This action will not change the scope of the company's consolidated financial statements and is not expected to negatively impact its financial condition or operating results [1] - The company will enhance management of the subsidiary's operations and implement effective risk management and control measures [1]

2025年10月29日公司发布的三季报数据显示，前三季度公司共实现营业收入1.59亿元，同比增长 27.48%，实现净利润1420.88万元，同比增长484.48%。（数据宝） 天目药业1月22日交易公开信息 天目药业(600671)今日下跌9.69%，全天换手率11.11%，成交额2.80亿元，振幅13.66%。龙虎榜数据显 示，营业部席位合计净卖出2092.58万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-9.83%上榜，营业部席位合计净卖出2092.58万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交9615.28万元，其中，买入成交额为 3761.35万元，卖出成交额为5853.93万元，合计净卖出2092.58万元。 具体来看，第一大买入营业部及卖出营业部均为高盛(中国)证券有限责任公司上海浦东新区世纪大道证 券营业部，买入金额为955.44万元，卖出金额为1522.57万元。 资金流向方面，今日该股主力资金净流出1792.06万元，其中，特大单净流出1121.35万元，大单资金净 流出670.70万元。近5日主力资金净流入2136.26万元。 | 买/ | 会员营业部名称 ...